AFF: Bone Density and Structure with BP Use Based on Poster FR0030 “Bone Density and Structure of...

6
AFF: Bone Density and Structure with BP Use Based on Poster FR0030 “Bone Density and Structure of Patients on Bisphosphonates with Atypical Femur Fractures” Angela Cheung, Jonathan Adachi, Robert Josse, Robert Bleakney, Christian Viellette, Aliya Khan, Moira Kapral, Sophie Jamal, Heather McDonald-Blumer, Earl Bogoch Friday, October 15, 2010 ASBMR 2010 Toronto, Ontario

Transcript of AFF: Bone Density and Structure with BP Use Based on Poster FR0030 “Bone Density and Structure of...

Page 1: AFF: Bone Density and Structure with BP Use Based on Poster FR0030 “Bone Density and Structure of Patients on Bisphosphonates with Atypical Femur Fractures”

AFF: Bone Density

and Structure with BP Use

Based on Poster FR0030

“Bone Density and Structure of Patients on Bisphosphonates

with Atypical Femur Fractures”

Angela Cheung, Jonathan Adachi, Robert Josse, Robert Bleakney, Christian Viellette,

Aliya Khan, Moira Kapral, Sophie Jamal, Heather McDonald-Blumer, Earl Bogoch

Friday, October 15, 2010

ASBMR 2010

Toronto, Ontario

Page 2: AFF: Bone Density and Structure with BP Use Based on Poster FR0030 “Bone Density and Structure of Patients on Bisphosphonates with Atypical Femur Fractures”

Method

• A cross-sectional study of 16 patients (15 female, 1 male) referred to

the University Health Network Osteoporosis (OP) Clinic for assessment of

atypical femoral fractures (AFFs)

• Each patient was assessed by an OP physician and all radiographs were independently reviewed by a

musculoskeletal radiologist as well as an OP

expert

• Areal BMD by DXA was performed at the lumbar spine, total hip and

femoral neck

• HR-pQCT was also carried out at the distal radius and tibia

HR-pQCT=High-resolution peripheral quantitative computed tomography

Page 3: AFF: Bone Density and Structure with BP Use Based on Poster FR0030 “Bone Density and Structure of Patients on Bisphosphonates with Atypical Femur Fractures”

Patient Characteristics

• Mean age was 67.2 years (range 46.4 to 88.1)

• Mean serum 25-(OH)-D close to the time of fracture was 93 nmol/L

(within the range felt to be sufficient)

• Mean duration of bisphosphonate (BP) use was 7.5 years (range 2 to 10.6)

• Chinese n=6, Indian n=2, European Canadian n=8

• 11 patients had comorbid conditions or medications (rheumatoid arthritis, pemphigus, liver

transplant, diabetes, cancer, steroid or warfarin use

Page 4: AFF: Bone Density and Structure with BP Use Based on Poster FR0030 “Bone Density and Structure of Patients on Bisphosphonates with Atypical Femur Fractures”

Results

• Mean BMD T-score at the lumbar spine, total hip and femoral neck were -0.68, -0.48 and -0.90,

respectively

• On HRpQCT scans, there was decreased cortical thickness

• Marked cortical porosity and a lack of trabecular structure with empty “holes” on many of the

scans

• These bone defects were not at the site of the fracture but at the wrist and the ankle

• On biopsy, there was low bone turnover but it was not adynamic bone disease per se

Page 5: AFF: Bone Density and Structure with BP Use Based on Poster FR0030 “Bone Density and Structure of Patients on Bisphosphonates with Atypical Femur Fractures”

HRpQCT Scans of Patients on BPs with AFFs

Page 6: AFF: Bone Density and Structure with BP Use Based on Poster FR0030 “Bone Density and Structure of Patients on Bisphosphonates with Atypical Femur Fractures”

Conclusions

• Patients on BP with AFFs have poor bone quality and structure

as measured by HRpQCT

• Results suggest that low bone turnover and increased mineralization may not

be the only explanation for AFFs